[1]	Ngan HY, Kohorn EI, Cole LA, et al. Trophoblastic disease[J]. Int J Gynaecol Obstet. 2012, 119 (Suppl 2):S130-S136. DOI:10.1016/S0020-7292(12)60026-5. Cited in this article [2]

[2]	Cole LA, Khanlian SA, Giddings A, et al. Gestational trophoblastic diseases:4. Presentation with persistent low positive human chorionic gonadotropin test results[J]. Gynecol Oncol, 2006, 102(2):165-172. DOI:10.1016/j.ygyno.2005.12.048. Cited in this article [2]

[3]	Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations[J]. Lancet, 2000, 355(9205):712-715. DOI:10.1016/S0140-6736(00)01324-6. Cited in this article [1]

[4]	Cole LA, Khanlian SA, Muller CY. Detection of perimenopause or postmenopause human chorionic gonadotropin:an unnecessary source of alarm[J]. Am J Obstet Gynecol, 2008, 198(3):275e1-275e7. DOI:10.1016/j.ajog.2007.09.034. Cited in this article [1]

[5]	Snyder JA, Haymond S, Parvin CA, et al. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women[J]. Clin Chem, 2005, 51(10):1830-1835. DOI:10.1373/clinchem.2005.053595. Cited in this article [1]

[6]	Cole LA. Familial HCG syndrome[J]. J Reprod Immunol, 2012, 93(1):52-57. DOI:10.1016/j.jri.2011.11.001. Cited in this article [1]

[7]	Qian XQ, Chen LL, Li BH, et al. Long-term outcome of patients with persistent low-level elevation of human chorionic gonadotrophin[J]. J Obstet Gynaecol Res, 2016, 42(6):694-700. DOI:10.1111/jog.12953. Cited in this article [1]

[8]	Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases[J]. Gynecol Oncol, 2010, 116(1):3-9. DOI:10.1016/j.ygyno.2009.09.028. Cited in this article [1]

[9]	Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155 Suppl 1(Suppl 1):86-93. DOI:10.1002/ijgo.13877. Cited in this article [1]

[10]	Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital[J]. Cancer, 1983, 52(9):1728-1735. DOI:10.1002/1097-0142(19831101)52:9<1728::aid-cncr2820520929>3.0.co;2-u. Cited in this article [1]

[11]	Xiao C, Yang J, Zhao J, et al. Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia:a 24-year experience in Peking union medical college hospital[J]. BMC Cancer, 2015,15:318. DOI:10.1186/s12885-015-1325-7. Cited in this article [1]

[12]	Huang M, Pinto A, Castillo RP, et al. Complete serologic response to Pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma[J]. J Clin Oncol, 2017, 35(27):3172-3174. DOI:10.1200/JCO.2017.74.4052. Cited in this article [1]

[13]	Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110):2343-2345. DOI:10.1016/S0140-6736(17)32894-5. Cited in this article [1]

[14]	Patel SP, Othus M, Chae YK, et al. A phase Ⅱ basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia[J]. Clin Cancer Res, 2024, 30(1):33-38. DOI:10.1158/1078-0432.CCR-23-2293. Cited in this article [1]

[15]	Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours[J]. Br J Cancer, 2019, 120(6):587-594. DOI:10.1038/s41416-019-0402-0. Cited in this article [1]

[16]	Peter S, Yutaka N, Roshan A, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours:a retrospective observational study[J]. Lancet, 2009, 374(9683):48-55. DOI:10.1016/S0140-6736(09)60618-8. Cited in this article [1]

[17]	Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor:A review of 108 cases and their implications for prognosis and treatment[J]. Gynecol Oncol, 2016, 142(1):102-108. DOI:10.1016/j.ygyno.2016.05.006. Cited in this article [1]

[18]	王丽娟, 王东雁, 林仲秋. 《2024 NCCN妊娠滋养细胞肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(12):1117-1124.DOI:10.19538/j.fk2023120115. Cited in this article [1]

[19]	王丽娟, 王东雁, 林海雪, 等. 《2023 NCCN妊娠滋养细胞肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(1):68-74.DOI:10.19538/j.fk2023010117. Cited in this article [1]